| 2025 | 2024 | |||
|---|---|---|---|---|
| Gross margin | 308,6 k € | +352.7% | -122,1 k € | |
| EBITDA | 173,1 k € | +220.8% | -143,4 k € | |
| Operating profit | -540,4 k € | +42.6% | -941,2 k € | |
| Profit/loss | -567,7 k € | +38.3% | -920,7 k € | |
| Equity | -72,5 k € | -129.6% | 245,1 k € | |
| Total assets | 863,7 k € | -22.4% | 1,1 M € | |
| Cash | 170,2 k € | -47.8% | 326,0 k € | |
| Debts | 927,2 k € | +6.8% | 868,4 k € | |
Source: Belgian Official Gazette
Private limited company · Leuven · incorporated on 09/06/2023
Private limited company loss-making in the latest fiscal year. Cash position declining (-47.8%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
Tavira Therapeutics is a Private limited company incorporated in 2023. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven.